Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells

Urology

Volumn 60, Issue 3, 2002, Pages 516-520

  Lee, Chang Ho ^a   Jin, Ren Jie ^b   Kwak, Cheol ^c   Jeong, Hyeon ^c   Park, Moon Soo ^c   Lee, Nam Kyu ^a,d   Lee, Sang Eun ^c,d  

^a Soonchunhyang University College of Medicine   (South Korea)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; CLUSTERIN; COMPLEMENTARY DNA;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFICACY; GENETIC TRANSFECTION; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

EID: 0036753752     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01806-X     Document Type: Article

References (14)

1. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma 1983-1993 . Semin Oncol. 22:1995;42-60.
2. Gerharz C.D., Ramp U., Dejosez M., et al. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas an important factor for evasion from negative growth control . Lab Invest. 79:1999;1521-1534.
3. Rosenberg M.E., Silkensen J. Clusterin physiologic and pathophysiologic considerations . Int J Biochem Cell Biol. 27:1995;633-645.
4. Sensibar J.A., Sutkowski D.M., Raffo A., et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 55:1995;2431-2437.
5. Sintich S.M., Steinberg J., Kozlowski J.M., et al. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate. 39:1999;87-93.
6. Miyake H., Nelson C., Rennie P.S., et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60:2000;2547-2554.
7. Parczyk K., Pilarsky C., Rachel U., et al. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol. 120:1994;186-188.
8. Rodenburg C.J., Nooter K., Herweijer H., et al. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol. 2:1991;305-306.
9. Schwartsmann G., Medina de Cunha F., Silveira L.A., et al. Brazilian Oncology Trials Group . Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). (letter) Ann Oncol. 2:1991;443.
10. Volm M., Mattern J., Efferth T., et al. Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anticancer Res. 12:1992;1063-1067.
11. Kolenko V., Uzzo R.G., Bukowski R., et al. Dead or dying necrosis versus apoptosis in caspase-deficient human renal cell carcinoma . Cancer Res. 59:1999;2838-2842.
12. Lakins J., Bennett S.A., Chen J.H., et al. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem. 273:1998;27887-27895.
13. Lee C., Sensibar J.A. Proteins of the rat prostate II synthesis of new proteins in the ventral lobe during castration-induced regression . J Urol. 138:1987;903-908.
14. French L.E., Wohlwend A., Sappino A.P., et al. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest. 93:1994;877-884.